We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Surgery of the Upper Intestine May Correct Diabetes

By HospiMedica staff writers
Posted on 21 Apr 2008
A new study shows that intestinal surgery may effectively cure type 2 diabetes, an approach that not only may change the way the disease is treated, but that introduces a new way of thinking about diabetes.

A researcher at the New York-Presbyterian Hospital/Weill Cornell Medical Center (New York, NY, USA) performed surgery in animals suffering from diabetes that showed that procedures based on gastrointestinal bypass of the upper small intestine (specifically the duodenum and jejunum) causing nutrients' passage to be diverted, reverses abnormalities of blood glucose regulation. More...
This diabetes remission was established independently of any weight loss, and even in subjects that were not obese. This, according to researcher, implies that the upper intestine of diabetic patients may be the site where an abnormal signal is produced, causing, or at least favoring, the development of the disease.

The researcher, Francesco Rubino, M.D., chief of gastrointestinal metabolic surgery at Weill Cornell, proposed that the explanation for this finding could be the ‘anti-incretin theory'. Incretins are gastrointestinal hormones produced in response to the transit of nutrients that boost insulin production. Because an excess of insulin can determine hypoglycemia, the body has a counter-regulatory mechanism (the ‘anti-incretin' mechanism), activated by the same passage of nutrients through the upper intestine. The latter mechanism would act to decrease both the secretion and the action of insulin. In healthy patients, a correct balance between incretin and anti-incretin factors maintains normal excursions of sugar levels in the bloodstream; however, in some individuals, the duodenum and jejunum may be producing too much of this anti-incretin, thereby reducing insulin secretion and blocking the action of insulin, ultimately resulting in type 2 diabetes. After gastrointestinal bypass procedures, the exclusion of the upper small intestine from the transit of nutrients may offset the abnormal production of anti-incretin, thereby resulting in remission of diabetes. The study was published in a special supplement to the February 2008 issue of Diabetes Care.

"It should not surprise anyone that surgically altering the bowel's anatomy affects the mechanisms that regulate blood sugar levels, eventually influencing diabetes,” said Dr. Rubino. "By answering the question of how diabetes surgery works, we may be answering the question of how diabetes itself works.”

"The lesson we have learned with diabetes surgery is that diabetes is not always a chronic and relentless disease, where the only possible treatment goal is just the control of hyperglycemia and minimization of the risk of complications. Gastrointestinal surgery offers the possibility of complete disease remission,” he added. "This is a major shift in the way we consider treatment goals for diabetes. It is unprecedented in the history of the disease.”


Related Links:
NewYork-Presbyterian Hospital/Weill Cornell Medical Center

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.